GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alaunos Therapeutics Inc (NAS:TCRT) » Definitions » 14-Day RSI

TCRT (Alaunos Therapeutics) 14-Day RSI : 43.69 (As of Mar. 04, 2025)


View and export this data going back to 2005. Start your Free Trial

What is Alaunos Therapeutics 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2025-03-04), Alaunos Therapeutics's 14-Day RSI is 43.69.

The industry rank for Alaunos Therapeutics's 14-Day RSI or its related term are showing as below:

TCRT's 14-Day RSI is ranked worse than
50.16% of 1519 companies
in the Biotechnology industry
Industry Median: 43.66 vs TCRT: 43.69

Competitive Comparison of Alaunos Therapeutics's 14-Day RSI

For the Biotechnology subindustry, Alaunos Therapeutics's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alaunos Therapeutics's 14-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alaunos Therapeutics's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Alaunos Therapeutics's 14-Day RSI falls into.



Alaunos Therapeutics  (NAS:TCRT) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alaunos Therapeutics  (NAS:TCRT) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Alaunos Therapeutics 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Alaunos Therapeutics's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Alaunos Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
2617 Bissonnet Street, Suite 225, Houston, TX, USA, 77005
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations.
Executives
Boyle Kevin S. Sr. director, officer: Chief Executive Officer C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON MA 02129
Robert Hofmeister director C/O TCR2 THERAPEUTICS INC., 100 BINNEY STREET, CAMBRIDGE MA 02142
Jaime Vieser director ONE FIRST AVENUE, PARRIS BUILDING 34, NAVY YARD PLAZA, BOSTON MA 02129
Robert W Postma director 141 MECOX ROAD, WATER MILL NY 11976
Michael Wong officer: VP, Finance C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BUILDING #34, BOSTON MA 02129
Abhishek K Srivastava officer: See Remarks C/O ALAUNOS THERAPEUTICS, INC., 8030 EL RIO ST., HOUSTON TX 77054
Holger Weis director C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON MA 02129
Christopher Bowden director 38 SIDNEY STREET, 2ND FLOOR, CAMBRIDGE MA 02139
Mary Thistle director C/O VIACELL, INC., 245 FIRST STREET, CAMBRIDGE MA 02142
James Huang director 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Drew Deniger officer: VP, Research & Development C/O ALAUNOS THERAPEUTICS, INC., 8030 EL RIO ST., HOUSTON TX 77054
Groot Eleanor De officer: EVP, Operations C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON MA 02129
Melinda Lackey officer: Senior Vice President, Legal C/O ZIOPHARM ONCOLOGY INC., 8030 EL RIO ST, HOUSTON TX 77054
Heidi Hagen director AASTROM BIOSCIENCES, INC., 24 FRANK LLOYD WRIGHT DRIVE, ANN ARBOR MI 48105
Raffaele Baffa officer: Chief Medical Officer C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON MA 02129

Alaunos Therapeutics Headlines

From GuruFocus

Q3 2021 ZIOPHARM Oncology Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q1 2022 Alaunos Therapeutics Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q3 2022 Alaunos Therapeutics Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q4 2020 ZIOPHARM Oncology Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q2 2022 Alaunos Therapeutics Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q3 2020 ZIOPHARM Oncology Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q2 2021 ZIOPHARM Oncology Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024